Market Overview

Noted Neurosurgeon Joseph Maroon, MD, FACS To Head Stemedica Medical & Scientific Advisory Board

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Joseph C. Maroon, MD, FACS Neurosurgeon, Vice Chairman and Professor of the Department of Neurological Surgery at the University of Pittsburgh Medical Center (UPMC) has agreed to serve as Chairman of the Company's Medical and Scientific Advisory Board. Dr. Maroon is also the Heindl Scholar in Neuroscience at UPMC.

San Diego, CA (PRWEB) November 19, 2012

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Joseph C. Maroon, MD, FACS Neurosurgeon, Vice Chairman and Professor of the Department of Neurological Surgery at the University of Pittsburgh Medical Center (UPMC) has agreed to serve as Chairman of the Company's Medical and Scientific Advisory Board. Dr. Maroon is also the Heindl Scholar in Neuroscience at UPMC.

Dr. Maroon is widely regarded as a premiere specialist in the surgical treatment of injuries and diseases of the brain and spine. His research into brain tumors, concussions and diseases of the spine have led to many innovative techniques for diagnosing and treating these disorders. He is the author of more than 250 peer-reviewed papers and 55 books or book chapters.

Dr. Maroon commented, “Stem cells are taking on an increasingly important role in the treatment of multiple neurological conditions. I have been impressed with Stemedica's credentials as a cGMP manufacturer of its proprietary lines of ischemic tolerant neural and mesenchymal stem cells that are licensed for use in clinical trials. These cells possess the important safety, potency, purity and immune-privileged characteristics that are needed in translational medicine. I look forward to helping to guide the Company's scientific and medical efforts as they move forward in the clinical trial process toward commercialization.”

David G. Armstrong, DPM, MD, PhD, professor of surgery and director of the Southern Arizona Limb Salvage Alliance (SALSA) at the University of Arizona Department of Surgery, and a current member of Stemedica's Scientific Advisory Board, commented, “I join my colleagues in welcoming Dr. Maroon. Many of the conditions targeted by Stemedica involve ischemia and nerve damage. Addressing these complicated disease mechanisms requires integrative, synergistic approaches among multiple specialists. Dr. Maroon brings a depth and breadth of experience that will be helpful in our efforts to help patients.”

William Maloney, MD, Professor and Chair, Stanford University School of Medicine Orthopaedic Surgery, and a Board member of Stemedica commented, “Strategically, Stemedica is strengthening affiliations with respected researchers and clinicians at the major medical institutions in the United States and abroad. The University of Pittsburgh is well-recognized as one of the leading centers for the evaluation and treatment of neurological trauma and is also one of the top institutions in stem cell research. Dr. Maroon has been a major contributor to the field of neurological trauma. I am personally delighted to welcome another strong academically-oriented physician to the Stemedica team.”

Nikolai Tankovich, MD, PhD, FASLMS, President and Chief Medical Officer of Stemedica commented, “Stemedica is honored to have a physician of Dr. Maroon's stature join our team. We look forward to working closely with him as we continue to grow our preclinical and clinical initiatives.”

Stemedica currently has three FDA-approved clinical trials for ischemic stroke, myocardial infarct and cutaneous photoaging. The Company anticipates additional FDA filings in the near term for clinical trials in diabetic foot ulcers, osteoarthritis, vascular dementia and spinal cord injury. Stemedica's Advisory Board currently includes clinical experts in these and other indications. Under Dr. Maroon's leadership, Stemedica will be expanding its Medical and Scientific Advisory Board.

About Stemedica Cell Technologies, Inc. http://www.stemedica.com
Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and myocardial infarct. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.

For more information regarding Stemedica Cell Technologies, Inc., contact Dave McGuigan at dmcguigan (at) stemedica.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebStemedica-ischemia/neurology-stem-cells/prweb10148213.htm

 

Around the Web, We're Loving...

Get Benzinga's Newsletters